Premium
ASSESSMENT OF THE CORONARY VASODILATOR ACTION OF SK&F 24260 IN THE DOG
Author(s) -
Narimatsu A.,
Satoh K.,
Taira N.
Publication year - 1978
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1978.tb00660.x
Subject(s) - microgram , coronary sinus , heart rate , blood pressure , coronary vasodilator , vasodilation , medicine , hemodynamics , fissipedia , cardiology , anesthesia , chemistry , biochemistry , in vitro
SUMMARY 1. The effects of SK&F 24260 administered intravenously or intraduodenally on the coronary sinus outflow, coronary arteriovenous oxygen difference (A‐V O 2 ), myocardial oxygen consumption (MVO 2 ), systemic blood pressure, heart rate and atrioventricular (AV) conduction time were examined in open‐chest dogs. 2. SK&F 24260 in doses of 0.3–10 μg/kg, i.v., caused a dose‐dependent increase in coronary sinus outflow, but the increase was smaller with 30 μg/kg, i.v., than with 10μg/kg, i.v. 3. SK&F 24260 (0.3–30μg/kg, i.v.) decreased A‐V O 2 and MVO 2 in a dose‐dependent manner. 4. SK& F 24260 (0.3–30μg/kg, i.v.) decreased systemic blood pressure and heart rate, and increased AV conduction time. 5. Intraduodenal administration of SK&F 24260 (1 mg/kg) produced almost the same effects on coronary sinus outflow, A‐V O 2 , MVO 2 , systemic blood pressure, heart rate and AV conduction time as did the intravenous administration of the compound (10μg/kg). 6. The property of SK&F 24260 to increase the coronary blood flow and to moderately decrease MVO 2 , systemic blood pressure and heart rate indicates that this agent is a potential antianginal drug.